SL

Sarah Lucas

Founder of Beyond Type 1

San Francisco Bay Area

Overview 

Sarah Lucas is a successful entrepreneur, investor, producer, and philanthropist currently serving as the Managing General Partner at Lucas Venture Group. She has a notable career as the Co-Founder and CEO of Beyond Type 1, a renowned organization in the health sector, and has made significant investments in various sectors including Robotics, BioTech, and AI. Sarah Lucas has achieved success as a Co-Founder and CEO of Beyond Type 1, a prominent health organization, and has effectively managed investments in diverse sectors such as Robotics and BioTech during her tenure as Managing General Partner at Lucas Venture Group.

Work Experience 

  • Managing General Partner

    2020 - Current

    Lucas Venture Group is a boutique, early-stage venture firm based in Silicon Valley, founded by second-generation venture capitalist Donald A. Lucas. Under the leadership of Managing General Partner Sarah Lucas and General Partner Jack Lucas, LVG invests in a diverse range of industries including AI & ML, SaaS, space, fintech, social purpose, CPG, and biotech. With a wealth of experience spanning over six decades in the venture space, LVG has built a wide-ranging network that offers entrepreneurs exceptional access to financial and intellectual capital. LVG takes a comprehensive approach to support the growth and success of its portfolio companies, providing not only financial backing but also strategic guidance and operational expertise. Recent exit highlights include Berkeley Lights, Palantir, and Truebill.

  • Partner

    2015 - 2020

Lucas Venture Group is a venture capital firm investing in robotics, networking, software analytics, big data, and cyber security.

  • Advisor

    2021

    Celesta Capital is a leading deep tech venture capital firm that invests in exceptional entrepreneurs and disruptive technologies. Through the firm’s unique mix of intellectual capital and network of relationships, Celesta empowers founding teams and drives continuous and measurable progress for its portfolio companies. Celesta Capital is led by Lip-Bu Tan, Michael Marks, Nicholas Brathwaite, and Sriram Viswanathan—industry veterans with proven track records. Together with a multi-dimensional and experienced investments and operations team, the firm supports the change-makers of tomorrow.

Celesta Capital is a venture capital firm that invests in entrepreneurs and disruptive technology companies.

  • Co-Founder Beyond Type 1

    2015

    Founded in 2015 by VC Juliet de Baubigny, musician Nick Jonas, philanthropist Sarah Lucas + celebrity chef Sam Talbot, Beyond Type 1 is focused on improving daily life and outcomes for those living with Type 1 diabetes. Leveraging the power social media, design and technology, Beyond Type 1 is a powerhouse global organization, tackling big issues - such as awareness + misdiagnosis - with simple, effective scalable systems, and shaking up the landscape in an effort to ensure access to treatments, information and technologies for living today while always investing in the long-term goal - a cure.

  • CEO + Co-Founder

    2015 - 2018

Beyond Type 1 is the largest diabetes org online, funding advocacy, education and cure research.

Raised $1,050,985.00 from The Leona M. and Harry B. Helmsley Charitable Trust and The Leona M. and Harry B. Helmsley Charitable Trust.

  • Founding Investor + Board Member

    2021

    BoldHue is transforming beauty with precision-matched foundation tailored to every unique skin tone. Using advanced color-matching technology and high-performance formulations, BoldHue delivers a seamless, personalized foundation experience that enhances natural beauty. With a commitment to inclusivity and innovation, the company is redefining complexion products to ensure everyone finds their perfect match.

  • Investor + Board Observer

    2024

    Minutia is a next-generation cell therapy company developing breakthrough treatments for chronic diseases. Its lead program is a functional cure for Type 1 diabetes, combining insulin-producing cell transplants with nanosensor technology to restore natural blood sugar regulation. By leveraging cutting-edge bioengineering and precision medicine, Minutia is redefining the future of cell therapies, with the potential to transform millions of lives.

  • Investor

    2024

    Ethos Space Resources is at the forefront of sustainable space exploration, developing advanced in-space resource utilization and extraction technologies. The company focuses on harnessing extraterrestrial materials to enable long-term human presence beyond Earth while driving innovation in the commercial space industry. Ethos is committed to responsible resource management and breakthrough engineering, paving the way for the future of space sustainability.

  • Founding Investor

    2024

    California Organic Fertilizer (COFI) is a leader in sustainable agriculture, specializing in high-quality organic fertilizers that enhance soil health and promote environmentally responsible farming. With a commitment to regenerative practices, COFI provides nutrient-rich solutions designed to improve crop yields while maintaining ecological balance. By prioritizing innovation and sustainability, COFI supports farmers in cultivating healthier, more productive soils for future generations.

  • Advisor

    2023

    Botrista Technology is revolutionizing beverage automation with its AI-driven **DrinkBot**, enabling businesses to serve high-quality craft drinks in seconds. Operating in 37 states, Botrista partners with a diverse range of establishments, including national restaurant chains, independent eateries, college campuses, movie theaters, and theme parks. Botrista’s innovative system enhances efficiency, consistency, and profitability.

Our automated Robot Barista increase beverage incidents and overall profit for F&B operators

Raised $125,751,000.00 from Jollibee Food.

  • Investor

    2021

    Prellis Biologics is pioneering the next generation of therapeutics by combining AI-driven drug discovery with bio printed human lymph nodes. This breakthrough approach enables fully human immune responses in vitro, accelerating the development of novel antibody therapies with unprecedented speed and precision. By leveraging advanced bio printing and computational biology, Prellis is transforming the future of immunotherapy and precision medicine.

Prellis employs holographic tissue printing technology with fully human antibody discovery, in vitro human disease and ADME/Tox models.

Raised $79,372,758.00 from SOSV, IndieBio, Lucas Venture Group, IndieBio, True Ventures, SOSV, Avidity Partners, Celesta Capital, Black Diamond Ventures and Khosla Ventures.

  • Investor

    2021

    ONX Homes is redefining homebuilding with an integrated, technology-driven approach that streamlines construction while enhancing quality and sustainability. By leveraging advanced prefabrication, proprietary design systems, and efficient on-site assembly, ONX delivers high-performance homes faster and with greater precision. The company’s innovative model is transforming the housing industry, making modern, resilient homes more accessible for communities across the country.

Onx Homes is an integrated DesignTech company that delivers beautiful homes, sustainable communities for every family.

Raised $119,991,040.00 from Serafund.

Articles About Sarah

Relevant Websites